nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—CYP1A1—head and neck cancer	0.316	1	CbGaD
Dasatinib—CYP1B1—Docetaxel—head and neck cancer	0.0467	0.31	CbGbCtD
Dasatinib—ABCG2—Fluorouracil—head and neck cancer	0.0291	0.193	CbGbCtD
Dasatinib—ABCG2—Docetaxel—head and neck cancer	0.0222	0.147	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—head and neck cancer	0.0123	0.0817	CbGbCtD
Dasatinib—CYP1A2—Fluorouracil—head and neck cancer	0.012	0.0796	CbGbCtD
Dasatinib—ABCB1—Vinblastine—head and neck cancer	0.00971	0.0645	CbGbCtD
Dasatinib—ABCB1—Docetaxel—head and neck cancer	0.008	0.0531	CbGbCtD
Dasatinib—CYP3A4—Vinblastine—head and neck cancer	0.00582	0.0386	CbGbCtD
Dasatinib—CYP3A4—Docetaxel—head and neck cancer	0.00479	0.0318	CbGbCtD
Dasatinib—RIPK2—parotid gland—head and neck cancer	0.000662	0.00475	CbGeAlD
Dasatinib—TEC—lymph node—head and neck cancer	0.000654	0.0047	CbGeAlD
Dasatinib—SIK2—head—head and neck cancer	0.000648	0.00465	CbGeAlD
Dasatinib—SIK1—parotid gland—head and neck cancer	0.000646	0.00464	CbGeAlD
Dasatinib—RIPK2—saliva-secreting gland—head and neck cancer	0.000634	0.00455	CbGeAlD
Dasatinib—PKMYT1—head—head and neck cancer	0.000631	0.00454	CbGeAlD
Dasatinib—CSK—connective tissue—head and neck cancer	0.000627	0.00451	CbGeAlD
Dasatinib—SIK1—saliva-secreting gland—head and neck cancer	0.000619	0.00445	CbGeAlD
Dasatinib—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.000618	0.00427	CcSEcCtD
Dasatinib—Rash erythematous—Docetaxel—head and neck cancer	0.000617	0.00426	CcSEcCtD
Dasatinib—Pleural effusion—Docetaxel—head and neck cancer	0.000617	0.00426	CcSEcCtD
Dasatinib—STAT5B—thyroid gland—head and neck cancer	0.000615	0.00442	CbGeAlD
Dasatinib—Angina pectoris—Vinblastine—head and neck cancer	0.000609	0.00421	CcSEcCtD
Dasatinib—ERBB3—saliva-secreting gland—head and neck cancer	0.000607	0.00436	CbGeAlD
Dasatinib—EPHB2—head—head and neck cancer	0.000602	0.00433	CbGeAlD
Dasatinib—Oesophagitis—Fluorouracil—head and neck cancer	0.000598	0.00413	CcSEcCtD
Dasatinib—Breast disorder—Hydroxyurea—head and neck cancer	0.000596	0.00412	CcSEcCtD
Dasatinib—Rash maculo-papular—Fluorouracil—head and neck cancer	0.000595	0.00411	CcSEcCtD
Dasatinib—Pancytopenia—Vinblastine—head and neck cancer	0.000594	0.0041	CcSEcCtD
Dasatinib—SRMS—head—head and neck cancer	0.000589	0.00423	CbGeAlD
Dasatinib—TXK—head—head and neck cancer	0.000583	0.00419	CbGeAlD
Dasatinib—RIPK2—connective tissue—head and neck cancer	0.000582	0.00418	CbGeAlD
Dasatinib—EPHA8—head—head and neck cancer	0.000577	0.00415	CbGeAlD
Dasatinib—TESK1—trachea—head and neck cancer	0.000575	0.00413	CbGeAlD
Dasatinib—EPHA3—thyroid gland—head and neck cancer	0.000569	0.00409	CbGeAlD
Dasatinib—SIK1—connective tissue—head and neck cancer	0.000569	0.00408	CbGeAlD
Dasatinib—Sepsis—Fluorouracil—head and neck cancer	0.000568	0.00392	CcSEcCtD
Dasatinib—FMO3—parotid gland—head and neck cancer	0.000567	0.00407	CbGeAlD
Dasatinib—ZAK—lymphoid tissue—head and neck cancer	0.000566	0.00407	CbGeAlD
Dasatinib—STK36—trachea—head and neck cancer	0.000566	0.00406	CbGeAlD
Dasatinib—EPHB3—trachea—head and neck cancer	0.000566	0.00406	CbGeAlD
Dasatinib—Pancreatitis—Hydroxyurea—head and neck cancer	0.000559	0.00386	CcSEcCtD
Dasatinib—EPHB4—parotid gland—head and neck cancer	0.000559	0.00402	CbGeAlD
Dasatinib—ERBB3—connective tissue—head and neck cancer	0.000557	0.004	CbGeAlD
Dasatinib—KIT—mouth—head and neck cancer	0.000557	0.004	CbGeAlD
Dasatinib—SIK3—thyroid gland—head and neck cancer	0.000553	0.00398	CbGeAlD
Dasatinib—RIPK2—epithelium—head and neck cancer	0.000553	0.00397	CbGeAlD
Dasatinib—MAP3K2—connective tissue—head and neck cancer	0.000552	0.00397	CbGeAlD
Dasatinib—LYN—lymphoid tissue—head and neck cancer	0.000551	0.00396	CbGeAlD
Dasatinib—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00055	0.0038	CcSEcCtD
Dasatinib—Thrombophlebitis—Fluorouracil—head and neck cancer	0.000549	0.00379	CcSEcCtD
Dasatinib—EPHA2—parotid gland—head and neck cancer	0.000548	0.00394	CbGeAlD
Dasatinib—LIMK2—trachea—head and neck cancer	0.000547	0.00393	CbGeAlD
Dasatinib—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000547	0.00378	CcSEcCtD
Dasatinib—Myocardial infarction—Vinblastine—head and neck cancer	0.000547	0.00378	CcSEcCtD
Dasatinib—STAT5B—head—head and neck cancer	0.000546	0.00392	CbGeAlD
Dasatinib—Pancytopenia—Hydroxyurea—head and neck cancer	0.000542	0.00374	CcSEcCtD
Dasatinib—Photosensitivity—Fluorouracil—head and neck cancer	0.000541	0.00374	CcSEcCtD
Dasatinib—BTK—lymphoid tissue—head and neck cancer	0.00054	0.00388	CbGeAlD
Dasatinib—EPHB4—saliva-secreting gland—head and neck cancer	0.000535	0.00385	CbGeAlD
Dasatinib—MAP4K5—parotid gland—head and neck cancer	0.000535	0.00384	CbGeAlD
Dasatinib—MAP3K3—parotid gland—head and neck cancer	0.000535	0.00384	CbGeAlD
Dasatinib—Neutropenia—Hydroxyurea—head and neck cancer	0.000533	0.00369	CcSEcCtD
Dasatinib—ERBB3—epithelium—head and neck cancer	0.000529	0.0038	CbGeAlD
Dasatinib—CSK—trachea—head and neck cancer	0.000527	0.00378	CbGeAlD
Dasatinib—EPHA2—saliva-secreting gland—head and neck cancer	0.000525	0.00377	CbGeAlD
Dasatinib—CYP1B1—hair follicle—head and neck cancer	0.000523	0.00376	CbGeAlD
Dasatinib—HCK—trachea—head and neck cancer	0.00052	0.00373	CbGeAlD
Dasatinib—Weight increased—Hydroxyurea—head and neck cancer	0.000519	0.00359	CcSEcCtD
Dasatinib—MAPK14—connective tissue—head and neck cancer	0.000519	0.00373	CbGeAlD
Dasatinib—ZAK—thyroid gland—head and neck cancer	0.000514	0.0037	CbGeAlD
Dasatinib—EPHB1—lymph node—head and neck cancer	0.000514	0.00369	CbGeAlD
Dasatinib—MAP4K5—saliva-secreting gland—head and neck cancer	0.000512	0.00368	CbGeAlD
Dasatinib—MAP3K3—saliva-secreting gland—head and neck cancer	0.000512	0.00368	CbGeAlD
Dasatinib—EPHB6—parotid gland—head and neck cancer	0.000511	0.00367	CbGeAlD
Dasatinib—Infestation NOS—Hydroxyurea—head and neck cancer	0.000509	0.00351	CcSEcCtD
Dasatinib—Infestation—Hydroxyurea—head and neck cancer	0.000509	0.00351	CcSEcCtD
Dasatinib—Amnesia—Fluorouracil—head and neck cancer	0.000506	0.00349	CcSEcCtD
Dasatinib—EPHA3—head—head and neck cancer	0.000505	0.00363	CbGeAlD
Dasatinib—Haemoglobin—Vinblastine—head and neck cancer	0.000503	0.00348	CcSEcCtD
Dasatinib—Haemorrhage—Vinblastine—head and neck cancer	0.000501	0.00346	CcSEcCtD
Dasatinib—Blood bilirubin increased—Docetaxel—head and neck cancer	0.000499	0.00345	CcSEcCtD
Dasatinib—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000499	0.00344	CcSEcCtD
Dasatinib—Stomatitis—Hydroxyurea—head and neck cancer	0.000496	0.00343	CcSEcCtD
Dasatinib—YES1—parotid gland—head and neck cancer	0.000494	0.00355	CbGeAlD
Dasatinib—BMPR1B—thyroid gland—head and neck cancer	0.000493	0.00354	CbGeAlD
Dasatinib—MAPK14—epithelium—head and neck cancer	0.000493	0.00354	CbGeAlD
Dasatinib—EPHB4—connective tissue—head and neck cancer	0.000492	0.00353	CbGeAlD
Dasatinib—SIK3—head—head and neck cancer	0.000491	0.00353	CbGeAlD
Dasatinib—BTK—thyroid gland—head and neck cancer	0.000491	0.00353	CbGeAlD
Dasatinib—EPHB6—saliva-secreting gland—head and neck cancer	0.00049	0.00352	CbGeAlD
Dasatinib—RIPK2—trachea—head and neck cancer	0.000489	0.00351	CbGeAlD
Dasatinib—JAK2—connective tissue—head and neck cancer	0.000489	0.00351	CbGeAlD
Dasatinib—Inflammation—Docetaxel—head and neck cancer	0.000487	0.00336	CcSEcCtD
Dasatinib—Cardiac failure—Fluorouracil—head and neck cancer	0.000487	0.00336	CcSEcCtD
Dasatinib—TNK2—thyroid gland—head and neck cancer	0.000484	0.00347	CbGeAlD
Dasatinib—FYN—connective tissue—head and neck cancer	0.000482	0.00346	CbGeAlD
Dasatinib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000481	0.00332	CcSEcCtD
Dasatinib—LIMK2—lymphoid tissue—head and neck cancer	0.000476	0.00342	CbGeAlD
Dasatinib—KIT—neck—head and neck cancer	0.000476	0.00342	CbGeAlD
Dasatinib—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000475	0.00328	CcSEcCtD
Dasatinib—YES1—saliva-secreting gland—head and neck cancer	0.000473	0.0034	CbGeAlD
Dasatinib—EPHA4—trachea—head and neck cancer	0.000473	0.00339	CbGeAlD
Dasatinib—Pulmonary embolism—Docetaxel—head and neck cancer	0.000472	0.00326	CcSEcCtD
Dasatinib—ERBB3—trachea—head and neck cancer	0.000468	0.00336	CbGeAlD
Dasatinib—EPHB4—epithelium—head and neck cancer	0.000467	0.00336	CbGeAlD
Dasatinib—PDGFRB—neck—head and neck cancer	0.000465	0.00334	CbGeAlD
Dasatinib—JAK2—epithelium—head and neck cancer	0.000464	0.00333	CbGeAlD
Dasatinib—Haemoglobin—Hydroxyurea—head and neck cancer	0.000459	0.00317	CcSEcCtD
Dasatinib—CSK—lymphoid tissue—head and neck cancer	0.000459	0.0033	CbGeAlD
Dasatinib—EPHA2—epithelium—head and neck cancer	0.000458	0.00329	CbGeAlD
Dasatinib—Haemorrhage—Hydroxyurea—head and neck cancer	0.000457	0.00315	CcSEcCtD
Dasatinib—ZAK—head—head and neck cancer	0.000456	0.00328	CbGeAlD
Dasatinib—TESK1—thyroid gland—head and neck cancer	0.000455	0.00327	CbGeAlD
Dasatinib—Colitis—Docetaxel—head and neck cancer	0.000454	0.00313	CcSEcCtD
Dasatinib—HCK—lymphoid tissue—head and neck cancer	0.000453	0.00325	CbGeAlD
Dasatinib—Skin exfoliation—Docetaxel—head and neck cancer	0.000451	0.00312	CcSEcCtD
Dasatinib—Fluid retention—Docetaxel—head and neck cancer	0.000448	0.0031	CcSEcCtD
Dasatinib—STK36—thyroid gland—head and neck cancer	0.000448	0.00322	CbGeAlD
Dasatinib—EPHA5—head—head and neck cancer	0.000447	0.00321	CbGeAlD
Dasatinib—LYN—head—head and neck cancer	0.000444	0.00319	CbGeAlD
Dasatinib—Neuropathy—Docetaxel—head and neck cancer	0.000443	0.00306	CcSEcCtD
Dasatinib—Alopecia—Vinblastine—head and neck cancer	0.000442	0.00306	CcSEcCtD
Dasatinib—BMPR1B—head—head and neck cancer	0.000438	0.00314	CbGeAlD
Dasatinib—MAP3K19—head—head and neck cancer	0.000438	0.00314	CbGeAlD
Dasatinib—MAP2K5—parotid gland—head and neck cancer	0.000437	0.00314	CbGeAlD
Dasatinib—Dry skin—Fluorouracil—head and neck cancer	0.000435	0.00301	CcSEcCtD
Dasatinib—YES1—connective tissue—head and neck cancer	0.000435	0.00312	CbGeAlD
Dasatinib—LCK—trachea—head and neck cancer	0.000434	0.00312	CbGeAlD
Dasatinib—LIMK2—thyroid gland—head and neck cancer	0.000433	0.00311	CbGeAlD
Dasatinib—Oesophagitis—Docetaxel—head and neck cancer	0.000432	0.00298	CcSEcCtD
Dasatinib—BMX—lymph node—head and neck cancer	0.000431	0.0031	CbGeAlD
Dasatinib—TNK2—head—head and neck cancer	0.000429	0.00308	CbGeAlD
Dasatinib—Neoplasm—Docetaxel—head and neck cancer	0.000427	0.00295	CcSEcCtD
Dasatinib—PDGFRA—connective tissue—head and neck cancer	0.000427	0.00306	CbGeAlD
Dasatinib—BLK—lymph node—head and neck cancer	0.000427	0.00306	CbGeAlD
Dasatinib—Pulmonary oedema—Docetaxel—head and neck cancer	0.00042	0.0029	CcSEcCtD
Dasatinib—STK35—thyroid gland—head and neck cancer	0.000419	0.00301	CbGeAlD
Dasatinib—Muscular weakness—Fluorouracil—head and neck cancer	0.000419	0.00289	CcSEcCtD
Dasatinib—MAP2K5—saliva-secreting gland—head and neck cancer	0.000419	0.00301	CbGeAlD
Dasatinib—SRC—connective tissue—head and neck cancer	0.000418	0.00301	CbGeAlD
Dasatinib—CSK—thyroid gland—head and neck cancer	0.000417	0.00299	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—head and neck cancer	0.000416	0.00299	CbGeAlD
Dasatinib—Angiopathy—Hydroxyurea—head and neck cancer	0.000414	0.00286	CcSEcCtD
Dasatinib—EPHB4—trachea—head and neck cancer	0.000413	0.00297	CbGeAlD
Dasatinib—HCK—thyroid gland—head and neck cancer	0.000411	0.00295	CbGeAlD
Dasatinib—Dysphagia—Fluorouracil—head and neck cancer	0.000411	0.00284	CcSEcCtD
Dasatinib—JAK2—trachea—head and neck cancer	0.00041	0.00295	CbGeAlD
Dasatinib—Sepsis—Docetaxel—head and neck cancer	0.00041	0.00283	CcSEcCtD
Dasatinib—Chills—Hydroxyurea—head and neck cancer	0.00041	0.00283	CcSEcCtD
Dasatinib—ABL2—thyroid gland—head and neck cancer	0.000409	0.00294	CbGeAlD
Dasatinib—TXK—lymph node—head and neck cancer	0.000408	0.00293	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—head and neck cancer	0.000408	0.00293	CbGeAlD
Dasatinib—EPHA2—trachea—head and neck cancer	0.000405	0.00291	CbGeAlD
Dasatinib—FYN—trachea—head and neck cancer	0.000405	0.00291	CbGeAlD
Dasatinib—Ill-defined disorder—Vinblastine—head and neck cancer	0.000404	0.00279	CcSEcCtD
Dasatinib—MAP3K2—lymphoid tissue—head and neck cancer	0.000404	0.0029	CbGeAlD
Dasatinib—TESK1—head—head and neck cancer	0.000403	0.0029	CbGeAlD
Dasatinib—Alopecia—Hydroxyurea—head and neck cancer	0.000403	0.00279	CcSEcCtD
Dasatinib—Anaemia—Vinblastine—head and neck cancer	0.000403	0.00278	CcSEcCtD
Dasatinib—Angina pectoris—Fluorouracil—head and neck cancer	0.0004	0.00276	CcSEcCtD
Dasatinib—Erythema—Hydroxyurea—head and neck cancer	0.000397	0.00275	CcSEcCtD
Dasatinib—SRC—epithelium—head and neck cancer	0.000397	0.00285	CbGeAlD
Dasatinib—STK36—head—head and neck cancer	0.000397	0.00285	CbGeAlD
Dasatinib—EPHB3—head—head and neck cancer	0.000397	0.00285	CbGeAlD
Dasatinib—Thrombophlebitis—Docetaxel—head and neck cancer	0.000396	0.00274	CcSEcCtD
Dasatinib—MAP4K5—trachea—head and neck cancer	0.000395	0.00284	CbGeAlD
Dasatinib—MAP3K3—trachea—head and neck cancer	0.000395	0.00284	CbGeAlD
Dasatinib—Malaise—Vinblastine—head and neck cancer	0.000393	0.00272	CcSEcCtD
Dasatinib—Vertigo—Vinblastine—head and neck cancer	0.000392	0.00271	CcSEcCtD
Dasatinib—Pancytopenia—Fluorouracil—head and neck cancer	0.00039	0.00269	CcSEcCtD
Dasatinib—KIT—parotid gland—head and neck cancer	0.000388	0.00278	CbGeAlD
Dasatinib—RIPK2—thyroid gland—head and neck cancer	0.000387	0.00278	CbGeAlD
Dasatinib—LIMK2—head—head and neck cancer	0.000384	0.00276	CbGeAlD
Dasatinib—STAT5B—lymph node—head and neck cancer	0.000382	0.00275	CbGeAlD
Dasatinib—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000382	0.00264	CcSEcCtD
Dasatinib—MAPK14—lymphoid tissue—head and neck cancer	0.000379	0.00273	CbGeAlD
Dasatinib—PDGFRB—parotid gland—head and neck cancer	0.000378	0.00272	CbGeAlD
Dasatinib—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000378	0.00261	CcSEcCtD
Dasatinib—FGR—lymphoid tissue—head and neck cancer	0.000378	0.00271	CbGeAlD
Dasatinib—EPHB6—trachea—head and neck cancer	0.000378	0.00271	CbGeAlD
Dasatinib—SIK1—thyroid gland—head and neck cancer	0.000378	0.00271	CbGeAlD
Dasatinib—Convulsion—Vinblastine—head and neck cancer	0.000378	0.00261	CcSEcCtD
Dasatinib—Hypertension—Vinblastine—head and neck cancer	0.000376	0.0026	CcSEcCtD
Dasatinib—CSF1R—connective tissue—head and neck cancer	0.000376	0.0027	CbGeAlD
Dasatinib—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000375	0.00259	CcSEcCtD
Dasatinib—EPHA4—thyroid gland—head and neck cancer	0.000374	0.00269	CbGeAlD
Dasatinib—STK35—head—head and neck cancer	0.000372	0.00267	CbGeAlD
Dasatinib—KIT—saliva-secreting gland—head and neck cancer	0.000371	0.00267	CbGeAlD
Dasatinib—ERBB3—thyroid gland—head and neck cancer	0.00037	0.00266	CbGeAlD
Dasatinib—CSK—head—head and neck cancer	0.00037	0.00266	CbGeAlD
Dasatinib—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000369	0.00255	CcSEcCtD
Dasatinib—Pneumonia—Fluorouracil—head and neck cancer	0.000368	0.00254	CcSEcCtD
Dasatinib—Anaemia—Hydroxyurea—head and neck cancer	0.000367	0.00254	CcSEcCtD
Dasatinib—Discomfort—Vinblastine—head and neck cancer	0.000367	0.00253	CcSEcCtD
Dasatinib—MAP3K2—thyroid gland—head and neck cancer	0.000367	0.00263	CbGeAlD
Dasatinib—Infestation NOS—Fluorouracil—head and neck cancer	0.000366	0.00253	CcSEcCtD
Dasatinib—Infestation—Fluorouracil—head and neck cancer	0.000366	0.00253	CcSEcCtD
Dasatinib—YES1—trachea—head and neck cancer	0.000365	0.00262	CbGeAlD
Dasatinib—HCK—head—head and neck cancer	0.000365	0.00262	CbGeAlD
Dasatinib—PDGFRB—saliva-secreting gland—head and neck cancer	0.000362	0.0026	CbGeAlD
Dasatinib—Atrial fibrillation—Docetaxel—head and neck cancer	0.000362	0.0025	CcSEcCtD
Dasatinib—Visual disturbance—Docetaxel—head and neck cancer	0.000362	0.0025	CcSEcCtD
Dasatinib—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000361	0.00249	CcSEcCtD
Dasatinib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000359	0.00248	CcSEcCtD
Dasatinib—Myocardial infarction—Fluorouracil—head and neck cancer	0.000359	0.00248	CcSEcCtD
Dasatinib—Malaise—Hydroxyurea—head and neck cancer	0.000358	0.00248	CcSEcCtD
Dasatinib—PDGFRA—trachea—head and neck cancer	0.000358	0.00257	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—head and neck cancer	0.000357	0.00257	CbGeAlD
Dasatinib—Stomatitis—Fluorouracil—head and neck cancer	0.000357	0.00247	CcSEcCtD
Dasatinib—Conjunctivitis—Fluorouracil—head and neck cancer	0.000356	0.00246	CcSEcCtD
Dasatinib—EPHA3—lymph node—head and neck cancer	0.000353	0.00254	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—head and neck cancer	0.000353	0.00254	CbGeAlD
Dasatinib—FYN—lymphoid tissue—head and neck cancer	0.000352	0.00253	CbGeAlD
Dasatinib—Cardiac failure—Docetaxel—head and neck cancer	0.000351	0.00243	CcSEcCtD
Dasatinib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000348	0.00241	CcSEcCtD
Dasatinib—Epistaxis—Fluorouracil—head and neck cancer	0.000345	0.00239	CcSEcCtD
Dasatinib—MAPK14—thyroid gland—head and neck cancer	0.000345	0.00248	CbGeAlD
Dasatinib—Convulsion—Hydroxyurea—head and neck cancer	0.000344	0.00238	CcSEcCtD
Dasatinib—MAP4K5—lymphoid tissue—head and neck cancer	0.000344	0.00247	CbGeAlD
Dasatinib—SIK3—lymph node—head and neck cancer	0.000344	0.00247	CbGeAlD
Dasatinib—FGR—thyroid gland—head and neck cancer	0.000343	0.00247	CbGeAlD
Dasatinib—LCK—thyroid gland—head and neck cancer	0.000343	0.00247	CbGeAlD
Dasatinib—RIPK2—head—head and neck cancer	0.000343	0.00246	CbGeAlD
Dasatinib—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000343	0.00237	CcSEcCtD
Dasatinib—KIT—connective tissue—head and neck cancer	0.000341	0.00245	CbGeAlD
Dasatinib—Anorexia—Vinblastine—head and neck cancer	0.000339	0.00234	CcSEcCtD
Dasatinib—ABL1—parotid gland—head and neck cancer	0.000337	0.00242	CbGeAlD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000336	0.00232	CcSEcCtD
Dasatinib—SIK1—head—head and neck cancer	0.000335	0.00241	CbGeAlD
Dasatinib—Discomfort—Hydroxyurea—head and neck cancer	0.000334	0.00231	CcSEcCtD
Dasatinib—PDGFRB—connective tissue—head and neck cancer	0.000333	0.00239	CbGeAlD
Dasatinib—EPHA4—head—head and neck cancer	0.000332	0.00238	CbGeAlD
Dasatinib—FMO3—thyroid gland—head and neck cancer	0.000332	0.00238	CbGeAlD
Dasatinib—Haemoglobin—Fluorouracil—head and neck cancer	0.00033	0.00228	CcSEcCtD
Dasatinib—Haemorrhage—Fluorouracil—head and neck cancer	0.000329	0.00227	CcSEcCtD
Dasatinib—ERBB3—head—head and neck cancer	0.000328	0.00236	CbGeAlD
Dasatinib—EPHB4—thyroid gland—head and neck cancer	0.000327	0.00235	CbGeAlD
Dasatinib—MAP3K2—head—head and neck cancer	0.000325	0.00234	CbGeAlD
Dasatinib—JAK2—thyroid gland—head and neck cancer	0.000324	0.00233	CbGeAlD
Dasatinib—Oedema—Hydroxyurea—head and neck cancer	0.000324	0.00224	CcSEcCtD
Dasatinib—KIT—epithelium—head and neck cancer	0.000324	0.00233	CbGeAlD
Dasatinib—ABL1—saliva-secreting gland—head and neck cancer	0.000323	0.00232	CbGeAlD
Dasatinib—MAP2K5—trachea—head and neck cancer	0.000323	0.00232	CbGeAlD
Dasatinib—Infection—Hydroxyurea—head and neck cancer	0.000322	0.00223	CcSEcCtD
Dasatinib—EPHA2—thyroid gland—head and neck cancer	0.000321	0.0023	CbGeAlD
Dasatinib—FYN—thyroid gland—head and neck cancer	0.00032	0.0023	CbGeAlD
Dasatinib—ZAK—lymph node—head and neck cancer	0.00032	0.0023	CbGeAlD
Dasatinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000318	0.0022	CcSEcCtD
Dasatinib—YES1—lymphoid tissue—head and neck cancer	0.000318	0.00228	CbGeAlD
Dasatinib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000318	0.00219	CcSEcCtD
Dasatinib—PDGFRB—epithelium—head and neck cancer	0.000316	0.00227	CbGeAlD
Dasatinib—CSF1R—trachea—head and neck cancer	0.000315	0.00226	CbGeAlD
Dasatinib—Skin disorder—Hydroxyurea—head and neck cancer	0.000315	0.00218	CcSEcCtD
Dasatinib—Dry skin—Docetaxel—head and neck cancer	0.000314	0.00217	CcSEcCtD
Dasatinib—MAP4K5—thyroid gland—head and neck cancer	0.000313	0.00225	CbGeAlD
Dasatinib—MAP3K3—thyroid gland—head and neck cancer	0.000313	0.00225	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—head and neck cancer	0.000312	0.00224	CbGeAlD
Dasatinib—Breast disorder—Docetaxel—head and neck cancer	0.00031	0.00214	CcSEcCtD
Dasatinib—Anorexia—Hydroxyurea—head and neck cancer	0.000309	0.00214	CcSEcCtD
Dasatinib—Decreased appetite—Vinblastine—head and neck cancer	0.000309	0.00214	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000309	0.00213	CcSEcCtD
Dasatinib—BMPR1B—lymph node—head and neck cancer	0.000306	0.0022	CbGeAlD
Dasatinib—SRC—lymphoid tissue—head and neck cancer	0.000306	0.0022	CbGeAlD
Dasatinib—MAPK14—head—head and neck cancer	0.000306	0.0022	CbGeAlD
Dasatinib—BTK—lymph node—head and neck cancer	0.000305	0.00219	CbGeAlD
Dasatinib—FGR—head—head and neck cancer	0.000305	0.00219	CbGeAlD
Dasatinib—Constipation—Vinblastine—head and neck cancer	0.000304	0.0021	CcSEcCtD
Dasatinib—Pain—Vinblastine—head and neck cancer	0.000304	0.0021	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000302	0.00209	CcSEcCtD
Dasatinib—TNK2—lymph node—head and neck cancer	0.0003	0.00216	CbGeAlD
Dasatinib—EPHB6—thyroid gland—head and neck cancer	0.000299	0.00215	CbGeAlD
Dasatinib—ABL1—connective tissue—head and neck cancer	0.000297	0.00213	CbGeAlD
Dasatinib—Dysphagia—Docetaxel—head and neck cancer	0.000296	0.00205	CcSEcCtD
Dasatinib—FMO3—head—head and neck cancer	0.000294	0.00211	CbGeAlD
Dasatinib—Arrhythmia—Fluorouracil—head and neck cancer	0.000294	0.00203	CcSEcCtD
Dasatinib—Feeling abnormal—Vinblastine—head and neck cancer	0.000293	0.00203	CcSEcCtD
Dasatinib—Bronchospasm—Docetaxel—head and neck cancer	0.000291	0.00201	CcSEcCtD
Dasatinib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000291	0.00201	CcSEcCtD
Dasatinib—Alopecia—Fluorouracil—head and neck cancer	0.00029	0.00201	CcSEcCtD
Dasatinib—CYP1A1—mouth—head and neck cancer	0.00029	0.00208	CbGeAlD
Dasatinib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000289	0.002	CcSEcCtD
Dasatinib—YES1—thyroid gland—head and neck cancer	0.000289	0.00207	CbGeAlD
Dasatinib—Angina pectoris—Docetaxel—head and neck cancer	0.000289	0.00199	CcSEcCtD
Dasatinib—Somnolence—Hydroxyurea—head and neck cancer	0.000288	0.00199	CcSEcCtD
Dasatinib—JAK2—head—head and neck cancer	0.000288	0.00207	CbGeAlD
Dasatinib—KIT—trachea—head and neck cancer	0.000286	0.00206	CbGeAlD
Dasatinib—Erythema—Fluorouracil—head and neck cancer	0.000286	0.00198	CcSEcCtD
Dasatinib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000286	0.00197	CcSEcCtD
Dasatinib—EPHA2—head—head and neck cancer	0.000284	0.00204	CbGeAlD
Dasatinib—FYN—head—head and neck cancer	0.000284	0.00204	CbGeAlD
Dasatinib—PDGFRA—thyroid gland—head and neck cancer	0.000283	0.00204	CbGeAlD
Dasatinib—TESK1—lymph node—head and neck cancer	0.000283	0.00203	CbGeAlD
Dasatinib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000282	0.00195	CcSEcCtD
Dasatinib—Pancytopenia—Docetaxel—head and neck cancer	0.000281	0.00194	CcSEcCtD
Dasatinib—Abdominal pain—Vinblastine—head and neck cancer	0.000281	0.00194	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00028	0.00193	CcSEcCtD
Dasatinib—Fatigue—Hydroxyurea—head and neck cancer	0.00028	0.00193	CcSEcCtD
Dasatinib—PDGFRB—trachea—head and neck cancer	0.00028	0.00201	CbGeAlD
Dasatinib—EPHB3—lymph node—head and neck cancer	0.000278	0.002	CbGeAlD
Dasatinib—STK36—lymph node—head and neck cancer	0.000278	0.002	CbGeAlD
Dasatinib—SRC—thyroid gland—head and neck cancer	0.000278	0.002	CbGeAlD
Dasatinib—MAP3K3—head—head and neck cancer	0.000277	0.00199	CbGeAlD
Dasatinib—MAP4K5—head—head and neck cancer	0.000277	0.00199	CbGeAlD
Dasatinib—Pain—Hydroxyurea—head and neck cancer	0.000277	0.00192	CcSEcCtD
Dasatinib—Constipation—Hydroxyurea—head and neck cancer	0.000277	0.00192	CcSEcCtD
Dasatinib—Neutropenia—Docetaxel—head and neck cancer	0.000277	0.00191	CcSEcCtD
Dasatinib—CSF1R—lymphoid tissue—head and neck cancer	0.000275	0.00197	CbGeAlD
Dasatinib—Weight increased—Docetaxel—head and neck cancer	0.00027	0.00186	CcSEcCtD
Dasatinib—Vision blurred—Fluorouracil—head and neck cancer	0.00027	0.00186	CcSEcCtD
Dasatinib—LIMK2—lymph node—head and neck cancer	0.000269	0.00193	CbGeAlD
Dasatinib—Weight decreased—Docetaxel—head and neck cancer	0.000268	0.00185	CcSEcCtD
Dasatinib—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000267	0.00185	CcSEcCtD
Dasatinib—Pneumonia—Docetaxel—head and neck cancer	0.000266	0.00184	CcSEcCtD
Dasatinib—EPHB6—head—head and neck cancer	0.000265	0.0019	CbGeAlD
Dasatinib—Anaemia—Fluorouracil—head and neck cancer	0.000264	0.00183	CcSEcCtD
Dasatinib—Infestation—Docetaxel—head and neck cancer	0.000264	0.00183	CcSEcCtD
Dasatinib—Infestation NOS—Docetaxel—head and neck cancer	0.000264	0.00183	CcSEcCtD
Dasatinib—Hypersensitivity—Vinblastine—head and neck cancer	0.000262	0.00181	CcSEcCtD
Dasatinib—STK35—lymph node—head and neck cancer	0.000261	0.00187	CbGeAlD
Dasatinib—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00026	0.0018	CcSEcCtD
Dasatinib—Renal failure—Docetaxel—head and neck cancer	0.00026	0.00179	CcSEcCtD
Dasatinib—Myocardial infarction—Docetaxel—head and neck cancer	0.000259	0.00179	CcSEcCtD
Dasatinib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000259	0.00179	CcSEcCtD
Dasatinib—CSK—lymph node—head and neck cancer	0.000259	0.00186	CbGeAlD
Dasatinib—Stomatitis—Docetaxel—head and neck cancer	0.000258	0.00178	CcSEcCtD
Dasatinib—Conjunctivitis—Docetaxel—head and neck cancer	0.000257	0.00177	CcSEcCtD
Dasatinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000256	0.00177	CcSEcCtD
Dasatinib—YES1—head—head and neck cancer	0.000256	0.00184	CbGeAlD
Dasatinib—MAP2K5—thyroid gland—head and neck cancer	0.000256	0.00184	CbGeAlD
Dasatinib—HCK—lymph node—head and neck cancer	0.000256	0.00184	CbGeAlD
Dasatinib—Asthenia—Vinblastine—head and neck cancer	0.000255	0.00176	CcSEcCtD
Dasatinib—ABL2—lymph node—head and neck cancer	0.000254	0.00182	CbGeAlD
Dasatinib—CYP1B1—connective tissue—head and neck cancer	0.000251	0.00181	CbGeAlD
Dasatinib—PDGFRA—head—head and neck cancer	0.000251	0.00181	CbGeAlD
Dasatinib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00025	0.00173	CcSEcCtD
Dasatinib—CSF1R—thyroid gland—head and neck cancer	0.000249	0.00179	CbGeAlD
Dasatinib—KIT—lymphoid tissue—head and neck cancer	0.000249	0.00179	CbGeAlD
Dasatinib—ABL1—trachea—head and neck cancer	0.000249	0.00179	CbGeAlD
Dasatinib—Epistaxis—Docetaxel—head and neck cancer	0.000249	0.00172	CcSEcCtD
Dasatinib—Convulsion—Fluorouracil—head and neck cancer	0.000248	0.00171	CcSEcCtD
Dasatinib—SRC—head—head and neck cancer	0.000246	0.00177	CbGeAlD
Dasatinib—Myalgia—Fluorouracil—head and neck cancer	0.000244	0.00168	CcSEcCtD
Dasatinib—Chest pain—Fluorouracil—head and neck cancer	0.000244	0.00168	CcSEcCtD
Dasatinib—PDGFRB—lymphoid tissue—head and neck cancer	0.000244	0.00175	CbGeAlD
Dasatinib—Diarrhoea—Vinblastine—head and neck cancer	0.000243	0.00168	CcSEcCtD
Dasatinib—Discomfort—Fluorouracil—head and neck cancer	0.000241	0.00166	CcSEcCtD
Dasatinib—RIPK2—lymph node—head and neck cancer	0.00024	0.00173	CbGeAlD
Dasatinib—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000239	0.00165	CcSEcCtD
Dasatinib—Haemoglobin—Docetaxel—head and neck cancer	0.000238	0.00165	CcSEcCtD
Dasatinib—Haemorrhage—Docetaxel—head and neck cancer	0.000237	0.00164	CcSEcCtD
Dasatinib—Hepatitis—Docetaxel—head and neck cancer	0.000237	0.00164	CcSEcCtD
Dasatinib—Confusional state—Fluorouracil—head and neck cancer	0.000235	0.00163	CcSEcCtD
Dasatinib—Dizziness—Vinblastine—head and neck cancer	0.000235	0.00163	CcSEcCtD
Dasatinib—SIK1—lymph node—head and neck cancer	0.000235	0.00169	CbGeAlD
Dasatinib—Urinary tract disorder—Docetaxel—head and neck cancer	0.000234	0.00162	CcSEcCtD
Dasatinib—Oedema peripheral—Docetaxel—head and neck cancer	0.000234	0.00161	CcSEcCtD
Dasatinib—Oedema—Fluorouracil—head and neck cancer	0.000233	0.00161	CcSEcCtD
Dasatinib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000233	0.00161	CcSEcCtD
Dasatinib—Asthenia—Hydroxyurea—head and neck cancer	0.000233	0.00161	CcSEcCtD
Dasatinib—Urethral disorder—Docetaxel—head and neck cancer	0.000233	0.00161	CcSEcCtD
Dasatinib—EPHA4—lymph node—head and neck cancer	0.000232	0.00167	CbGeAlD
Dasatinib—Infection—Fluorouracil—head and neck cancer	0.000232	0.0016	CcSEcCtD
Dasatinib—ERBB3—lymph node—head and neck cancer	0.00023	0.00165	CbGeAlD
Dasatinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000229	0.00158	CcSEcCtD
Dasatinib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000229	0.00158	CcSEcCtD
Dasatinib—Visual impairment—Docetaxel—head and neck cancer	0.000229	0.00158	CcSEcCtD
Dasatinib—Tachycardia—Fluorouracil—head and neck cancer	0.000228	0.00157	CcSEcCtD
Dasatinib—MAP3K2—lymph node—head and neck cancer	0.000228	0.00164	CbGeAlD
Dasatinib—MAP2K5—head—head and neck cancer	0.000227	0.00163	CbGeAlD
Dasatinib—KIT—thyroid gland—head and neck cancer	0.000226	0.00163	CbGeAlD
Dasatinib—Vomiting—Vinblastine—head and neck cancer	0.000226	0.00156	CcSEcCtD
Dasatinib—Erythema multiforme—Docetaxel—head and neck cancer	0.000224	0.00155	CcSEcCtD
Dasatinib—Headache—Vinblastine—head and neck cancer	0.000223	0.00154	CcSEcCtD
Dasatinib—Anorexia—Fluorouracil—head and neck cancer	0.000223	0.00154	CcSEcCtD
Dasatinib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000222	0.00153	CcSEcCtD
Dasatinib—Eye disorder—Docetaxel—head and neck cancer	0.000222	0.00153	CcSEcCtD
Dasatinib—CSF1R—head—head and neck cancer	0.000221	0.00159	CbGeAlD
Dasatinib—PDGFRB—thyroid gland—head and neck cancer	0.000221	0.00159	CbGeAlD
Dasatinib—Flushing—Docetaxel—head and neck cancer	0.00022	0.00152	CcSEcCtD
Dasatinib—Cardiac disorder—Docetaxel—head and neck cancer	0.00022	0.00152	CcSEcCtD
Dasatinib—Hypotension—Fluorouracil—head and neck cancer	0.000218	0.00151	CcSEcCtD
Dasatinib—ABL1—lymphoid tissue—head and neck cancer	0.000217	0.00156	CbGeAlD
Dasatinib—Angiopathy—Docetaxel—head and neck cancer	0.000215	0.00149	CcSEcCtD
Dasatinib—Dizziness—Hydroxyurea—head and neck cancer	0.000215	0.00148	CcSEcCtD
Dasatinib—Immune system disorder—Docetaxel—head and neck cancer	0.000214	0.00148	CcSEcCtD
Dasatinib—MAPK14—lymph node—head and neck cancer	0.000214	0.00154	CbGeAlD
Dasatinib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000214	0.00148	CcSEcCtD
Dasatinib—FGR—lymph node—head and neck cancer	0.000213	0.00153	CbGeAlD
Dasatinib—LCK—lymph node—head and neck cancer	0.000213	0.00153	CbGeAlD
Dasatinib—Chills—Docetaxel—head and neck cancer	0.000213	0.00147	CcSEcCtD
Dasatinib—ABCG2—parotid gland—head and neck cancer	0.000213	0.00153	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000213	0.00147	CcSEcCtD
Dasatinib—Arrhythmia—Docetaxel—head and neck cancer	0.000212	0.00146	CcSEcCtD
Dasatinib—Nausea—Vinblastine—head and neck cancer	0.000211	0.00146	CcSEcCtD
Dasatinib—Insomnia—Fluorouracil—head and neck cancer	0.000211	0.00146	CcSEcCtD
Dasatinib—Alopecia—Docetaxel—head and neck cancer	0.00021	0.00145	CcSEcCtD
Dasatinib—Dyspnoea—Fluorouracil—head and neck cancer	0.000208	0.00144	CcSEcCtD
Dasatinib—Mental disorder—Docetaxel—head and neck cancer	0.000208	0.00144	CcSEcCtD
Dasatinib—Somnolence—Fluorouracil—head and neck cancer	0.000208	0.00143	CcSEcCtD
Dasatinib—Malnutrition—Docetaxel—head and neck cancer	0.000206	0.00143	CcSEcCtD
Dasatinib—Erythema—Docetaxel—head and neck cancer	0.000206	0.00143	CcSEcCtD
Dasatinib—Vomiting—Hydroxyurea—head and neck cancer	0.000206	0.00143	CcSEcCtD
Dasatinib—FMO3—lymph node—head and neck cancer	0.000206	0.00148	CbGeAlD
Dasatinib—Dyspepsia—Fluorouracil—head and neck cancer	0.000206	0.00142	CcSEcCtD
Dasatinib—Rash—Hydroxyurea—head and neck cancer	0.000205	0.00141	CcSEcCtD
Dasatinib—Dermatitis—Hydroxyurea—head and neck cancer	0.000204	0.00141	CcSEcCtD
Dasatinib—ABCG2—saliva-secreting gland—head and neck cancer	0.000204	0.00146	CbGeAlD
Dasatinib—Headache—Hydroxyurea—head and neck cancer	0.000203	0.0014	CcSEcCtD
Dasatinib—EPHB4—lymph node—head and neck cancer	0.000203	0.00146	CbGeAlD
Dasatinib—Decreased appetite—Fluorouracil—head and neck cancer	0.000203	0.0014	CcSEcCtD
Dasatinib—Dysgeusia—Docetaxel—head and neck cancer	0.000202	0.0014	CcSEcCtD
Dasatinib—CYP1A1—parotid gland—head and neck cancer	0.000202	0.00145	CbGeAlD
Dasatinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000202	0.00139	CcSEcCtD
Dasatinib—JAK2—lymph node—head and neck cancer	0.000202	0.00145	CbGeAlD
Dasatinib—KIT—head—head and neck cancer	0.000201	0.00144	CbGeAlD
Dasatinib—Pain—Fluorouracil—head and neck cancer	0.0002	0.00138	CcSEcCtD
Dasatinib—EPHA2—lymph node—head and neck cancer	0.000199	0.00143	CbGeAlD
Dasatinib—FYN—lymph node—head and neck cancer	0.000199	0.00143	CbGeAlD
Dasatinib—Muscle spasms—Docetaxel—head and neck cancer	0.000199	0.00137	CcSEcCtD
Dasatinib—ABL1—thyroid gland—head and neck cancer	0.000197	0.00142	CbGeAlD
Dasatinib—PDGFRB—head—head and neck cancer	0.000196	0.00141	CbGeAlD
Dasatinib—MAP3K3—lymph node—head and neck cancer	0.000194	0.0014	CbGeAlD
Dasatinib—MAP4K5—lymph node—head and neck cancer	0.000194	0.0014	CbGeAlD
Dasatinib—Nausea—Hydroxyurea—head and neck cancer	0.000193	0.00133	CcSEcCtD
Dasatinib—Feeling abnormal—Fluorouracil—head and neck cancer	0.000192	0.00133	CcSEcCtD
Dasatinib—Anaemia—Docetaxel—head and neck cancer	0.000191	0.00132	CcSEcCtD
Dasatinib—EPHB6—lymph node—head and neck cancer	0.000186	0.00133	CbGeAlD
Dasatinib—Urticaria—Fluorouracil—head and neck cancer	0.000185	0.00128	CcSEcCtD
Dasatinib—Syncope—Docetaxel—head and neck cancer	0.000185	0.00128	CcSEcCtD
Dasatinib—Body temperature increased—Fluorouracil—head and neck cancer	0.000185	0.00128	CcSEcCtD
Dasatinib—CYP1B1—lymphoid tissue—head and neck cancer	0.000184	0.00132	CbGeAlD
Dasatinib—Palpitations—Docetaxel—head and neck cancer	0.000182	0.00126	CcSEcCtD
Dasatinib—Loss of consciousness—Docetaxel—head and neck cancer	0.000181	0.00125	CcSEcCtD
Dasatinib—Cough—Docetaxel—head and neck cancer	0.00018	0.00124	CcSEcCtD
Dasatinib—YES1—lymph node—head and neck cancer	0.000179	0.00129	CbGeAlD
Dasatinib—Convulsion—Docetaxel—head and neck cancer	0.000179	0.00124	CcSEcCtD
Dasatinib—Hypertension—Docetaxel—head and neck cancer	0.000178	0.00123	CcSEcCtD
Dasatinib—PDGFRA—lymph node—head and neck cancer	0.000176	0.00126	CbGeAlD
Dasatinib—Myalgia—Docetaxel—head and neck cancer	0.000176	0.00121	CcSEcCtD
Dasatinib—Chest pain—Docetaxel—head and neck cancer	0.000176	0.00121	CcSEcCtD
Dasatinib—Arthralgia—Docetaxel—head and neck cancer	0.000176	0.00121	CcSEcCtD
Dasatinib—ABL1—head—head and neck cancer	0.000175	0.00126	CbGeAlD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000175	0.00121	CcSEcCtD
Dasatinib—SRC—lymph node—head and neck cancer	0.000173	0.00124	CbGeAlD
Dasatinib—Hypersensitivity—Fluorouracil—head and neck cancer	0.000172	0.00119	CcSEcCtD
Dasatinib—Confusional state—Docetaxel—head and neck cancer	0.00017	0.00117	CcSEcCtD
Dasatinib—CYP1A1—epithelium—head and neck cancer	0.000169	0.00121	CbGeAlD
Dasatinib—Oedema—Docetaxel—head and neck cancer	0.000169	0.00116	CcSEcCtD
Dasatinib—Infection—Docetaxel—head and neck cancer	0.000167	0.00116	CcSEcCtD
Dasatinib—CYP1B1—thyroid gland—head and neck cancer	0.000167	0.0012	CbGeAlD
Dasatinib—Shock—Docetaxel—head and neck cancer	0.000166	0.00115	CcSEcCtD
Dasatinib—Nervous system disorder—Docetaxel—head and neck cancer	0.000165	0.00114	CcSEcCtD
Dasatinib—Pruritus—Fluorouracil—head and neck cancer	0.000165	0.00114	CcSEcCtD
Dasatinib—Thrombocytopenia—Docetaxel—head and neck cancer	0.000165	0.00114	CcSEcCtD
Dasatinib—Tachycardia—Docetaxel—head and neck cancer	0.000164	0.00114	CcSEcCtD
Dasatinib—Skin disorder—Docetaxel—head and neck cancer	0.000164	0.00113	CcSEcCtD
Dasatinib—Anorexia—Docetaxel—head and neck cancer	0.000161	0.00111	CcSEcCtD
Dasatinib—Diarrhoea—Fluorouracil—head and neck cancer	0.00016	0.0011	CcSEcCtD
Dasatinib—MAP2K5—lymph node—head and neck cancer	0.000159	0.00114	CbGeAlD
Dasatinib—Hypotension—Docetaxel—head and neck cancer	0.000157	0.00109	CcSEcCtD
Dasatinib—CSF1R—lymph node—head and neck cancer	0.000155	0.00111	CbGeAlD
Dasatinib—Dizziness—Fluorouracil—head and neck cancer	0.000154	0.00107	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000154	0.00106	CcSEcCtD
Dasatinib—Insomnia—Docetaxel—head and neck cancer	0.000152	0.00105	CcSEcCtD
Dasatinib—Dyspnoea—Docetaxel—head and neck cancer	0.00015	0.00104	CcSEcCtD
Dasatinib—Somnolence—Docetaxel—head and neck cancer	0.00015	0.00104	CcSEcCtD
Dasatinib—CYP1A1—trachea—head and neck cancer	0.000149	0.00107	CbGeAlD
Dasatinib—Vomiting—Fluorouracil—head and neck cancer	0.000148	0.00103	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—head and neck cancer	0.000148	0.00102	CcSEcCtD
Dasatinib—CYP1B1—head—head and neck cancer	0.000148	0.00106	CbGeAlD
Dasatinib—Rash—Fluorouracil—head and neck cancer	0.000147	0.00102	CcSEcCtD
Dasatinib—Dermatitis—Fluorouracil—head and neck cancer	0.000147	0.00102	CcSEcCtD
Dasatinib—Decreased appetite—Docetaxel—head and neck cancer	0.000146	0.00101	CcSEcCtD
Dasatinib—Headache—Fluorouracil—head and neck cancer	0.000146	0.00101	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000145	0.00101	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—head and neck cancer	0.000145	0.001	CcSEcCtD
Dasatinib—Pain—Docetaxel—head and neck cancer	0.000144	0.000996	CcSEcCtD
Dasatinib—Constipation—Docetaxel—head and neck cancer	0.000144	0.000996	CcSEcCtD
Dasatinib—KIT—lymph node—head and neck cancer	0.000141	0.00101	CbGeAlD
Dasatinib—Feeling abnormal—Docetaxel—head and neck cancer	0.000139	0.00096	CcSEcCtD
Dasatinib—Nausea—Fluorouracil—head and neck cancer	0.000139	0.000958	CcSEcCtD
Dasatinib—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000138	0.000952	CcSEcCtD
Dasatinib—PDGFRB—lymph node—head and neck cancer	0.000137	0.000987	CbGeAlD
Dasatinib—Body temperature increased—Docetaxel—head and neck cancer	0.000133	0.00092	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—head and neck cancer	0.000133	0.00092	CcSEcCtD
Dasatinib—ABCG2—thyroid gland—head and neck cancer	0.000124	0.000893	CbGeAlD
Dasatinib—Hypersensitivity—Docetaxel—head and neck cancer	0.000124	0.000858	CcSEcCtD
Dasatinib—ABL1—lymph node—head and neck cancer	0.000122	0.00088	CbGeAlD
Dasatinib—Asthenia—Docetaxel—head and neck cancer	0.000121	0.000835	CcSEcCtD
Dasatinib—CYP1A2—thyroid gland—head and neck cancer	0.00012	0.00086	CbGeAlD
Dasatinib—Pruritus—Docetaxel—head and neck cancer	0.000119	0.000824	CcSEcCtD
Dasatinib—CYP1A1—thyroid gland—head and neck cancer	0.000118	0.000848	CbGeAlD
Dasatinib—Diarrhoea—Docetaxel—head and neck cancer	0.000115	0.000797	CcSEcCtD
Dasatinib—Dizziness—Docetaxel—head and neck cancer	0.000111	0.00077	CcSEcCtD
Dasatinib—Vomiting—Docetaxel—head and neck cancer	0.000107	0.00074	CcSEcCtD
Dasatinib—Rash—Docetaxel—head and neck cancer	0.000106	0.000734	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—head and neck cancer	0.000106	0.000733	CcSEcCtD
Dasatinib—Headache—Docetaxel—head and neck cancer	0.000106	0.000729	CcSEcCtD
Dasatinib—CYP1A1—head—head and neck cancer	0.000105	0.000752	CbGeAlD
Dasatinib—CYP1B1—lymph node—head and neck cancer	0.000104	0.000745	CbGeAlD
Dasatinib—Nausea—Docetaxel—head and neck cancer	0.0001	0.000692	CcSEcCtD
Dasatinib—ABCB1—epithelium—head and neck cancer	8.76e-05	0.00063	CbGeAlD
Dasatinib—ABCB1—trachea—head and neck cancer	7.75e-05	0.000557	CbGeAlD
Dasatinib—ABCG2—lymph node—head and neck cancer	7.72e-05	0.000555	CbGeAlD
Dasatinib—CYP1A1—lymph node—head and neck cancer	7.33e-05	0.000527	CbGeAlD
Dasatinib—ABCB1—lymphoid tissue—head and neck cancer	6.75e-05	0.000485	CbGeAlD
Dasatinib—ABCB1—thyroid gland—head and neck cancer	6.13e-05	0.00044	CbGeAlD
Dasatinib—ABCB1—head—head and neck cancer	5.44e-05	0.000391	CbGeAlD
Dasatinib—ABCB1—lymph node—head and neck cancer	3.81e-05	0.000274	CbGeAlD
Dasatinib—PDGFRB—Disease—MAPK1—head and neck cancer	3.52e-06	1.41e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—head and neck cancer	3.52e-06	1.41e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—head and neck cancer	3.51e-06	1.41e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—MAPK1—head and neck cancer	3.49e-06	1.4e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—head and neck cancer	3.49e-06	1.4e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—head and neck cancer	3.48e-06	1.4e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTEN—head and neck cancer	3.47e-06	1.39e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MAPK3—head and neck cancer	3.4e-06	1.36e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—head and neck cancer	3.39e-06	1.36e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—MAPK1—head and neck cancer	3.39e-06	1.36e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—head and neck cancer	3.39e-06	1.36e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—DPYD—head and neck cancer	3.39e-06	1.36e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PIK3CA—head and neck cancer	3.39e-06	1.36e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MAPK3—head and neck cancer	3.39e-06	1.36e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—STAT3—head and neck cancer	3.36e-06	1.35e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PTEN—head and neck cancer	3.36e-06	1.35e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—head and neck cancer	3.35e-06	1.35e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—PTEN—head and neck cancer	3.33e-06	1.33e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOTCH1—head and neck cancer	3.32e-06	1.33e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—PIK3CA—head and neck cancer	3.32e-06	1.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—PIK3CA—head and neck cancer	3.31e-06	1.33e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—head and neck cancer	3.31e-06	1.33e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—PIK3CA—head and neck cancer	3.3e-06	1.33e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—AKT1—head and neck cancer	3.29e-06	1.32e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—PIK3CA—head and neck cancer	3.24e-06	1.3e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MAPK1—head and neck cancer	3.23e-06	1.3e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—head and neck cancer	3.23e-06	1.3e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—head and neck cancer	3.23e-06	1.3e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—MAPK1—head and neck cancer	3.22e-06	1.29e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—head and neck cancer	3.22e-06	1.29e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—PIK3CA—head and neck cancer	3.22e-06	1.29e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—head and neck cancer	3.22e-06	1.29e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—YAP1—head and neck cancer	3.21e-06	1.29e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—MAPK3—head and neck cancer	3.21e-06	1.29e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—head and neck cancer	3.21e-06	1.29e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—head and neck cancer	3.21e-06	1.29e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PIK3CA—head and neck cancer	3.2e-06	1.28e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—PIK3CA—head and neck cancer	3.18e-06	1.28e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—STAT3—head and neck cancer	3.18e-06	1.27e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—head and neck cancer	3.17e-06	1.27e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—head and neck cancer	3.16e-06	1.27e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—head and neck cancer	3.15e-06	1.26e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—head and neck cancer	3.14e-06	1.26e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—head and neck cancer	3.13e-06	1.26e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TYMS—head and neck cancer	3.13e-06	1.26e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	3.13e-06	1.26e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—STAT3—head and neck cancer	3.1e-06	1.25e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—head and neck cancer	3.1e-06	1.24e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTM1—head and neck cancer	3.1e-06	1.24e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTEN—head and neck cancer	3.09e-06	1.24e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—head and neck cancer	3.09e-06	1.24e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTEN—head and neck cancer	3.07e-06	1.23e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—head and neck cancer	3.07e-06	1.23e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—head and neck cancer	3.07e-06	1.23e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PIK3CA—head and neck cancer	3.07e-06	1.23e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—head and neck cancer	3.07e-06	1.23e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—head and neck cancer	3.06e-06	1.23e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—MAPK1—head and neck cancer	3.06e-06	1.23e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—head and neck cancer	3.06e-06	1.23e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PIK3CA—head and neck cancer	3.05e-06	1.22e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—head and neck cancer	3.04e-06	1.22e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MAPK3—head and neck cancer	3.03e-06	1.22e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—head and neck cancer	3.03e-06	1.21e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—head and neck cancer	3.03e-06	1.21e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—head and neck cancer	3.02e-06	1.21e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	3.02e-06	1.21e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—head and neck cancer	3.01e-06	1.21e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—head and neck cancer	3e-06	1.2e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—head and neck cancer	2.99e-06	1.2e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—head and neck cancer	2.99e-06	1.2e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—head and neck cancer	2.98e-06	1.2e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—head and neck cancer	2.98e-06	1.2e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—head and neck cancer	2.98e-06	1.19e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MAPK3—head and neck cancer	2.97e-06	1.19e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GPX1—head and neck cancer	2.96e-06	1.19e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—head and neck cancer	2.96e-06	1.19e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—head and neck cancer	2.96e-06	1.19e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—head and neck cancer	2.96e-06	1.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—head and neck cancer	2.95e-06	1.18e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—head and neck cancer	2.95e-06	1.18e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—head and neck cancer	2.94e-06	1.18e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP1A1—head and neck cancer	2.94e-06	1.18e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—head and neck cancer	2.92e-06	1.17e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—head and neck cancer	2.92e-06	1.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—head and neck cancer	2.91e-06	1.17e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MAPK1—head and neck cancer	2.89e-06	1.16e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—head and neck cancer	2.89e-06	1.16e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—head and neck cancer	2.87e-06	1.15e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK3—head and neck cancer	2.87e-06	1.15e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK3—head and neck cancer	2.84e-06	1.14e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—head and neck cancer	2.84e-06	1.14e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—head and neck cancer	2.82e-06	1.13e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MAPK1—head and neck cancer	2.82e-06	1.13e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—head and neck cancer	2.82e-06	1.13e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—head and neck cancer	2.82e-06	1.13e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—head and neck cancer	2.81e-06	1.13e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—head and neck cancer	2.81e-06	1.13e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—head and neck cancer	2.8e-06	1.12e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—head and neck cancer	2.8e-06	1.12e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—head and neck cancer	2.77e-06	1.11e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—head and neck cancer	2.77e-06	1.11e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—head and neck cancer	2.75e-06	1.1e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—head and neck cancer	2.74e-06	1.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK1—head and neck cancer	2.73e-06	1.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—head and neck cancer	2.73e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.73e-06	1.09e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—head and neck cancer	2.72e-06	1.09e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—head and neck cancer	2.71e-06	1.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—head and neck cancer	2.71e-06	1.09e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—head and neck cancer	2.71e-06	1.09e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—head and neck cancer	2.71e-06	1.09e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK1—head and neck cancer	2.71e-06	1.09e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—head and neck cancer	2.7e-06	1.09e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—head and neck cancer	2.7e-06	1.08e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—head and neck cancer	2.68e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—head and neck cancer	2.65e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—head and neck cancer	2.65e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—head and neck cancer	2.64e-06	1.06e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—head and neck cancer	2.64e-06	1.06e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—head and neck cancer	2.63e-06	1.06e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—head and neck cancer	2.63e-06	1.05e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—head and neck cancer	2.61e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—head and neck cancer	2.61e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—head and neck cancer	2.6e-06	1.04e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—head and neck cancer	2.6e-06	1.04e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—head and neck cancer	2.59e-06	1.04e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—head and neck cancer	2.59e-06	1.04e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—head and neck cancer	2.58e-06	1.04e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—head and neck cancer	2.54e-06	1.02e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—head and neck cancer	2.53e-06	1.02e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—head and neck cancer	2.52e-06	1.01e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—head and neck cancer	2.51e-06	1.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—head and neck cancer	2.51e-06	1.01e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—head and neck cancer	2.51e-06	1.01e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—head and neck cancer	2.51e-06	1.01e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—head and neck cancer	2.5e-06	1e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK1—head and neck cancer	2.5e-06	1e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—head and neck cancer	2.5e-06	1e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—head and neck cancer	2.49e-06	1e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—head and neck cancer	2.49e-06	1e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—head and neck cancer	2.49e-06	9.99e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—head and neck cancer	2.48e-06	9.96e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—head and neck cancer	2.47e-06	9.92e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—head and neck cancer	2.47e-06	9.92e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK1—head and neck cancer	2.46e-06	9.88e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—head and neck cancer	2.46e-06	9.88e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—head and neck cancer	2.45e-06	9.84e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—head and neck cancer	2.45e-06	9.82e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—head and neck cancer	2.43e-06	9.75e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—head and neck cancer	2.42e-06	9.72e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK1—head and neck cancer	2.41e-06	9.67e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—head and neck cancer	2.41e-06	9.67e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—head and neck cancer	2.4e-06	9.64e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—head and neck cancer	2.4e-06	9.63e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK1—head and neck cancer	2.37e-06	9.52e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—head and neck cancer	2.37e-06	9.52e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—head and neck cancer	2.37e-06	9.51e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—head and neck cancer	2.37e-06	9.51e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX1—head and neck cancer	2.37e-06	9.5e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—head and neck cancer	2.35e-06	9.42e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1A1—head and neck cancer	2.34e-06	9.4e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—head and neck cancer	2.32e-06	9.3e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—head and neck cancer	2.31e-06	9.28e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—head and neck cancer	2.29e-06	9.2e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—head and neck cancer	2.29e-06	9.19e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—head and neck cancer	2.29e-06	9.17e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK1—head and neck cancer	2.29e-06	9.17e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—head and neck cancer	2.28e-06	9.17e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—head and neck cancer	2.28e-06	9.16e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—head and neck cancer	2.27e-06	9.09e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK1—head and neck cancer	2.26e-06	9.05e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—head and neck cancer	2.26e-06	9.05e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—head and neck cancer	2.23e-06	8.94e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—head and neck cancer	2.2e-06	8.81e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—head and neck cancer	2.19e-06	8.8e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—head and neck cancer	2.19e-06	8.77e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—head and neck cancer	2.18e-06	8.76e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—head and neck cancer	2.17e-06	8.72e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—head and neck cancer	2.17e-06	8.71e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—head and neck cancer	2.17e-06	8.7e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—head and neck cancer	2.17e-06	8.69e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—head and neck cancer	2.15e-06	8.63e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—head and neck cancer	2.14e-06	8.57e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—head and neck cancer	2.09e-06	8.39e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—head and neck cancer	2.08e-06	8.33e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—head and neck cancer	2.07e-06	8.29e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—head and neck cancer	2.06e-06	8.26e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—head and neck cancer	2.05e-06	8.21e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—head and neck cancer	2.02e-06	8.12e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—head and neck cancer	2.02e-06	8.09e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—head and neck cancer	2.01e-06	8.04e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—head and neck cancer	2e-06	8.02e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—head and neck cancer	1.99e-06	7.99e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—head and neck cancer	1.99e-06	7.97e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—head and neck cancer	1.98e-06	7.95e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—head and neck cancer	1.98e-06	7.93e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK1—head and neck cancer	1.98e-06	7.93e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—head and neck cancer	1.98e-06	7.92e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—head and neck cancer	1.96e-06	7.85e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—head and neck cancer	1.94e-06	7.8e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—head and neck cancer	1.94e-06	7.77e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—head and neck cancer	1.94e-06	7.76e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—head and neck cancer	1.93e-06	7.74e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.92e-06	7.72e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—head and neck cancer	1.92e-06	7.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—head and neck cancer	1.92e-06	7.7e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—head and neck cancer	1.92e-06	7.69e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.91e-06	7.65e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—head and neck cancer	1.91e-06	7.65e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—head and neck cancer	1.91e-06	7.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—head and neck cancer	1.89e-06	7.6e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—head and neck cancer	1.84e-06	7.37e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—head and neck cancer	1.83e-06	7.36e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX1—head and neck cancer	1.83e-06	7.33e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—head and neck cancer	1.81e-06	7.27e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.81e-06	7.25e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—head and neck cancer	1.78e-06	7.16e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—head and neck cancer	1.77e-06	7.1e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK1—head and neck cancer	1.75e-06	7.02e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—head and neck cancer	1.75e-06	7.02e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—head and neck cancer	1.75e-06	7e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—head and neck cancer	1.75e-06	7e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—head and neck cancer	1.71e-06	6.88e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—head and neck cancer	1.71e-06	6.85e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—head and neck cancer	1.68e-06	6.75e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—head and neck cancer	1.66e-06	6.65e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—head and neck cancer	1.62e-06	6.51e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—head and neck cancer	1.62e-06	6.5e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—head and neck cancer	1.6e-06	6.42e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—head and neck cancer	1.59e-06	6.36e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—head and neck cancer	1.52e-06	6.11e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—head and neck cancer	1.52e-06	6.09e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—head and neck cancer	1.47e-06	5.89e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—head and neck cancer	1.42e-06	5.71e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—head and neck cancer	1.4e-06	5.63e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—head and neck cancer	1.4e-06	5.62e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—head and neck cancer	1.39e-06	5.59e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—head and neck cancer	1.34e-06	5.39e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—head and neck cancer	1.24e-06	4.97e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—head and neck cancer	1.22e-06	4.88e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—head and neck cancer	1.16e-06	4.66e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—head and neck cancer	1.1e-06	4.41e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.08e-06	4.31e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—head and neck cancer	1.07e-06	4.31e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—head and neck cancer	9.38e-07	3.76e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—head and neck cancer	8.77e-07	3.52e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—head and neck cancer	8.57e-07	3.44e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—head and neck cancer	7e-07	2.81e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	6.62e-07	2.65e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—head and neck cancer	5.4e-07	2.17e-06	CbGpPWpGaD
